REGENERON PHARMACEUTICALS, INC. Equity Securities, FV-NI, Gain (Loss)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Equity Securities, FV-NI, Gain (Loss) of $955.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was -$22.50M.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $581.50M, a 332.34% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2024-12-31 was -$213.10M.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for the quarter ending 2024-09-30 was $134.50M.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for fiscal 2025 was $955.60M, a 711.89% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for fiscal 2024 was $117.70M.
- REGENERON PHARMACEUTICALS, INC. equity securities, fv-ni, gain (loss) for fiscal 2023 was -$235.60M.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$22.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $559.00M derived: sum of 2 quarters · filed 2026-02-04 | $955.60M 10-K · filed 2026-02-04 | |
| 2025-09-30 | $581.50M 10-Q · filed 2025-10-28 | $978.10M 10-Q · filed 2025-10-28 | ||
| 2024-12-31 | -$213.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | -$78.60M derived: sum of 2 quarters · filed 2026-02-04 | $117.70M 10-K · filed 2026-02-04 | |
| 2024-09-30 | $134.50M 10-Q · filed 2025-10-28 | $330.80M 10-Q · filed 2025-10-28 | ||
| 2023-12-31 | -$235.60M 10-K · filed 2026-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |